Investor Presentation Q1 2022

15 Investor presentation First three months of 2022 Concizumab reduced the number of bleeds in adults and adolescents with inhibitors in the Explorer 7 trial 100 Annualised bleeding rate per patient group Median Mean Key highlights Annualised Bleeding Rate (ABR) 90 40 40 30 20 20 10 9.8 OnD treatment PPX treatment PPX treatment 0 PPX treatment HWI (Group 1) Novo NordiskⓇ • Efficacy • • Median ABR was 0 for concizumab prophylaxis treatment, compared to 9.8 in the on-demand treatment group Estimated mean ABR was 1.7 for concizumab prophylaxis treatment, compared to 11.8 in the on-demand treatment group For patients on concizumab prophylaxis, 64% had 0 bleeds in Group 2 Safety Concizumab appeared to have a safe and well tolerated profile Next steps US submission for inhibitor indications expected later in 2022 Explorer 8 in non-inhibitor patients is ongoing US submission for non-inhibitor indications (HA/HB), and EU submission in all indications, expected in 2023 HWI (Group 2) HAWI (Groups 1-4) HBWI (Groups 1-4) • . Primary endpoint Note: The box represents Q1-Q3 (25th to 75th percentile). Whiskers are illustrative for 5th and 95th percentile. HA: Haemophilia A; HB: Haemophilia B; HAWI: Haemophilia A with inhibitors, HBwI: Haemophilia B with inhibitors; OnD: On-demand; PPX: Prophylaxis; ABR: Annualised bleeding rate

View entire presentation